Axsome Therapeutics Inc. (NASDAQ:AXSM) finished Wednesday with a subtraction of -$2.47 to close at $70.07, a downside of -3.41 percent. An average of 1,201,720 shares of common stock have been traded in the last five days. There was a fall of -$3.19 in the past week, and it reached a new high 18 times over the past 12 months. The last 20 days have seen an average of 853,950 shares traded, while the 50-day average volume stands at 973,996.
AXSM stock has decreased by -5.26% in the last month. The company shares reached their 1-month lowest point of $69.43 on 08/09/23. With the stock rallying to its 52-week high on 06/22/23, shares of the company touched a low of $38.87 and a high of $91.29 in 52 weeks. It has reached a new high 8 times so far this year and lost -9.15% or -$7.06 in price. In spite of this, the price is down -23.24% from the 52-week high.
Valuation Metrics
Axsome Therapeutics Inc. (AXSM) stock’s beta is 1.88. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 23.27, the price-to-book (PB) ratio at 27.26.
Financial Health
The quick ratio of Axsome Therapeutics Inc. for the three months ended June 29 was 2.90, and the current ratio was 3.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.32 and a total debt to equity ratio of 1.32 for the quarter ending June 29. Axsome Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -340.62%. Its gross profit as reported stood at $44.84 million compared to revenue of $50.04 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Axsome Therapeutics Inc.’s return on assets was -51.20%.
Earnings Surprise
For the three-month period that ended June 29, Axsome Therapeutics Inc. had $176.82 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$67.17 million in the quarter, while revenues of -$11.22 million were grew 38.31%. The analyst consensus anticipated Axsome Therapeutics Inc.’s latest quarter earnings to come in at -$1.22 per share, but it turned out to be -$1.54, a -26.20% surprise. For the quarter, EBITDA amounted to -$62.0 million. Shareholders own equity worth $47.19 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Axsome Therapeutics Inc. (AXSM) price momentum. RSI 9-day as of the close on 09 August was 35.19%, suggesting the stock is Neutral, with historical volatility in this time frame at 41.37%.
As of today, AXSM’s price is $72.53 -4.35% or -$3.19 from its 5-day moving average. AXSM is currently trading -5.58% lower than its 20-day SMA and +10.80% higher than its 100-day SMA. However, the stock’s current price level is +0.39% above the SMA50 and +58.49% above the SMA200.
The stochastic %K and %D were 17.61% and 23.15%, respectively, and the average true range (ATR) was 3.54. With the 14-day stochastic at 6.39% and the average true range at 3.38, the RSI (14) stands at 39.19%. The stock has reached -3.25 on the 9-day MACD Oscillator while the 14-day reading was at -3.46.
Analyst Ratings
BofA Securities upgraded Axsome Therapeutics Inc. (NASDAQ: AXSM) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Underperform. The consensus rating for Axsome Therapeutics Inc. (AXSM) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AXSM, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 10 others rate it as a “buy”.
What is AXSM’s price target for the next 12 months?
Analysts predict a range of price targets between $81.00 and $180.00, with a median target of $107.26. Taking a look at these predictions, the average price target given by analysts for Axsome Therapeutics Inc. (AXSM) stock is $115.21.
